Skip to main content

Month: July 2021

EcoChain, Inc. to Report Monthly Site Level Financials on July 14th

ALBANY, N.Y., July 08, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — EcoChain, Inc. (“EcoChain”), a wholly-owned subsidiary of Mechanical Technology, Incorporated (“MTI” or the “Company”), (NASDAQ: MKTY), a cryptocurrency mining business powered by renewable energy, today announced due to the July 4th holiday it now plans to release site level results for the month of June 2021 on July 14th. About EcoChain, Inc. EcoChain, Inc., a wholly-owned subsidiary of Mechanical Technology, Incorporated, is engaged in developing and operating ultra-low cost green data centers focused on cryptocurrency mining. For more information about EcoChain, please visit www.ecochainmining.com. Forward Looking Statement This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995....

Continue reading

Descartes Acquires GreenMile

Strengthens Final-Mile Distribution Capabilities WATERLOO, Ontario, July 08, 2021 (GLOBE NEWSWIRE) — Descartes Systems Group (TSX:DSG) (Nasdaq:DSGX), the global leader in uniting logistics-intensive businesses in commerce, announced that it has acquired GreenMile, a leading provider of cloud-based mobile route execution solutions for food, beverage, and broader distribution verticals. GreenMile’s highly scalable mobile route execution solutions have been built with unique capabilities to serve the global distribution industry. Customers benefit from a next-generation platform that incorporates machine-learning to continually improve service and travel time standards. GreenMile’s innovative solutions are used by some of the world’s largest food and beverage companies to digitize final-mile delivery processes, thereby eliminating...

Continue reading

Global WholeHealth Partners Corp (OTC:GWHP) Ships Its First Shipment of Over 20,000 Tests to Salud Previa of Tijuana, MX; Salud Previa Has Indicated That It Plans on Purchasing More Than 500,000 Tests Over the Next 12 Months

San Clemente, CA, July 08, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Global WholeHealth Partners Corp. (OTC: GWHP) offers one of the largest lines of COVID 19 tests. Global WholeHealth Partners Corp (OTC: GWHP) states that the Antibody IgG/IgM tests that they offer are capable of detecting all the current identified SARS-CoV-2 viruses.  The strains identified in the United Kingdom (B.1.1.7), South Africa (B.1.351), and Brazil (P.1) strain contain multiple mutations, most reflected in the S gene, which encodes the spike protein. Global understands the need to be ahead of the virus to conquer the virus. Global WholeHealth Partners recognizes that there is a crucial need for faster testing and faster results when it comes to fighting the COVID. Global WholeHealth Partners knows that the quicker the test results can be reviewed...

Continue reading

XPO Logistics Introduces Major New Benefits for Driver Trainees

Students receive full compensation and benefits during seven-week training, in addition to 100% paid tuition GREENWICH, Conn. , July 08, 2021 (GLOBE NEWSWIRE) — XPO Logistics, Inc. (NYSE: XPO), a leading global provider of transportation and logistics solutions, has unveiled a roster of new benefits for participants in its driver training programs, effective immediately. XPO, a top three less-than-truckload (LTL) carrier in North America, has been providing professional driver training nationally for more than 35 years. The company’s recent enhancements to student compensation and training options are designed to provide industry-best career paths, with access to schools in approximately 30 states and the flexibility to arrange local attendance. XPO driver trainees realize substantial value, including:Comprehensive training in...

Continue reading

Aclaris Therapeutics to Participate in the William Blair Biotech Focus Conference 2021

WAYNE, Pa., July 08, 2021 (GLOBE NEWSWIRE) — Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, President and CEO of Aclaris, will participate in a virtual panel discussion at the William Blair Biotech Focus Conference 2021 titled “Novel Targets for Autoimmune Diseases,” on Thursday, July 15, 2021 at 11:00 a.m. ET. Management will be available July 15th throughout the day for virtual one-on-one meetings. A live webcast of the panel discussion may be accessed through the “Events” page of the “Investors” section of Aclaris’ website, www.aclaristx.com. The webcast will be archived for at least 30 days on the Aclaris website. About Aclaris Therapeutics, Inc. Aclaris Therapeutics, Inc....

Continue reading

View, Inc. Acquires IoTium, a Pioneer in Secure Edge-Cloud Infrastructure for Smart Buildings

MILPITAS, Calif., July 08, 2021 (GLOBE NEWSWIRE) — View, Inc. (Nasdaq: VIEW) (“View”), the leader in smart building platforms and smart windows, today announced it has acquired IoTium, the leading provider of secure, cloud-managed, software-defined IoT networks. IoTium’s easy-to-deploy solutions enable building owners to quickly achieve enterprise-grade security, reduce operating costs, and gain real-time visibility into their entire real estate portfolios. “View’s smart building platform makes it easy to securely deploy a wide variety of smart building applications,” said Nitesh Trikha, Chief Product Officer at View. “IoTium’s edge-cloud solution makes the deployment process even easier, especially in existing buildings with legacy networks and systems. It is the most reliable, easiest-to-deploy and most economical solution to...

Continue reading

StorageVault to Acquire 2 GTA Storage Locations for $11.1 Million

TORONTO, July 08, 2021 (GLOBE NEWSWIRE) — STORAGEVAULT CANADA INC. (“StorageVault”) (SVI-TSX-V) has agreed to acquire 2 GTA stores from 2 vendor groups (collectively, the “Vendors”) for an aggregate purchase price of $11,122,000, subject to customary adjustments (the “Acquisitions”). Both Acquisitions are arm’s length. It is anticipated that the Acquisitions will close in Q3 2021. Purchase Price and PaymentThe aggregate purchase price is $11,122,000, subject to adjustments, and is payable by the issuance of an aggregate of up to approximately $4,250,000 of StorageVault common shares based on an agreed upon VWAP ending two days prior to closing, with the remainder of the aggregate purchase price being paid with funds on hand and mortgage financing. Conditions Precedent to the AcquisitionsThe obligations of StorageVault to complete...

Continue reading

Trevena Announces First Patient Enrolled in OLINVYK® Phase 3 Trial in China in Partnership with Jiangsu Nhwa Pharmaceutical

Nhwa is conducting and funding this study to support NDA regulatory filing in China Trevena expects to receive approval and commercialization milestones, and a 10% royalty on net sales in China CHESTERBROOK, Pa., July 08, 2021 (GLOBE NEWSWIRE) — Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced the Company’s partner in China has enrolled the first patient in a Phase 3 trial for OLINVYK (oliceridine) injection, a novel IV analgesic approved in the U.S. by the Food and Drug Administration (FDA) for acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. “We are committed to delivering OLINVYK to patients and healthcare...

Continue reading

Pluristem Brings ARDS Associated with COVID-19 Phase II Studies to Clinical Readout

The company will analyze data based on patients enrolled to date in COVID-19 Phase II studies in U.S., Europe and IsraelTopline results are expected during the fourth quarter of 2021HAIFA, Israel, July 08, 2021 (GLOBE NEWSWIRE) — Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI) (the “Company”), a leading biotechnology company announced today that it is bringing its Acute Respiratory Distress Syndrome (ARDS) associated with COVID-19 Phase II studies to clinical readout. The Company’s COVID-19 program included over 100 patients across two Phase II studies in the U.S., Europe and Israel, and in compassionate use and expanded access programs in the U.S. and Israel. The analysis will be based on 89 patients enrolled in the previously announced two Phase II studies, which investigated the safety and efficacy of Pluristem’s...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.